BNP Paribas Financial Markets raised its position in shares of Perspective Therapeutics, Inc. (NYSE:CATX – Free Report) by 1,302.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 47,565 shares of the company’s stock after purchasing an additional 44,174 shares during the period. BNP Paribas Financial Markets owned 0.07% of Perspective Therapeutics worth $635,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also bought and sold shares of CATX. WealthPlan Investment Management LLC purchased a new stake in shares of Perspective Therapeutics in the third quarter worth $4,530,000. Hills Bank & Trust Co bought a new position in Perspective Therapeutics in the 3rd quarter worth about $13,722,000. Nicholson Wealth Management Group LLC purchased a new stake in shares of Perspective Therapeutics in the 3rd quarter valued at about $21,390,000. FMR LLC boosted its position in shares of Perspective Therapeutics by 3,994.9% during the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after acquiring an additional 5,370,392 shares during the last quarter. Finally, WealthPLAN Partners LLC purchased a new position in shares of Perspective Therapeutics during the second quarter worth about $1,695,000. 54.66% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
CATX has been the topic of several research reports. UBS Group began coverage on shares of Perspective Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $20.00 price target on the stock. Oppenheimer decreased their target price on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research report on Friday, November 22nd. Royal Bank of Canada cut their price target on shares of Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating for the company in a research report on Monday, November 25th. Bank of America downgraded Perspective Therapeutics from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $24.00 to $5.00 in a report on Monday, November 25th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Perspective Therapeutics in a report on Monday, September 9th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $15.14.
Insider Transactions at Perspective Therapeutics
In other news, CEO Johan M. Spoor purchased 8,000 shares of the stock in a transaction that occurred on Wednesday, December 4th. The shares were purchased at an average cost of $3.77 per share, with a total value of $30,160.00. Following the completion of the acquisition, the chief executive officer now owns 36,257 shares of the company’s stock, valued at approximately $136,688.89. This represents a 28.31 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Jonathan Robert Hunt purchased 12,829 shares of Perspective Therapeutics stock in a transaction that occurred on Monday, November 25th. The stock was acquired at an average cost of $3.82 per share, with a total value of $49,006.78. Following the acquisition, the chief financial officer now directly owns 48,800 shares in the company, valued at $186,416. This trade represents a 35.66 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 67,570 shares of company stock valued at $256,789. Corporate insiders own 3.52% of the company’s stock.
Perspective Therapeutics Price Performance
Shares of NYSE CATX opened at $3.47 on Friday. Perspective Therapeutics, Inc. has a 1 year low of $2.28 and a 1 year high of $19.05. The firm has a 50-day simple moving average of $8.99 and a two-hundred day simple moving average of $11.59.
Perspective Therapeutics (NYSE:CATX – Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.21). The company had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. On average, sell-side analysts expect that Perspective Therapeutics, Inc. will post -0.88 EPS for the current fiscal year.
Perspective Therapeutics Profile
Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.
Further Reading
- Five stocks we like better than Perspective Therapeutics
- 3 Healthcare Dividend Stocks to Buy
- WallStreetBets: How a Reddit Forum Shook Up Stock Market Dynamics
- Why Invest in 5G? How to Invest in 5G Stocks
- Are 2024’s Top Insider Buys a Good Bet for 2025?
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- 4 Social Media Stocks to Soar as TikTok’s Future Hangs in Balance
Want to see what other hedge funds are holding CATX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Perspective Therapeutics, Inc. (NYSE:CATX – Free Report).
Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.